Business context and reporting period
AmerisourceBergen Corporation (NYSE: ABC), now Cencora, filed this Form 10-K for the fiscal year ended September 30, 2020. The company distributes pharmaceuticals and provides related services to healthcare providers and manufacturers, alongside global commercialization and animal-health businesses. Although the request refers to 2020 Q4, this is an annual filing; quarterly figures are noted separately below.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $189.9 billion | $179.6 billion |
| Gross profit | $5.192 billion | $5.138 billion |
| Operating income (loss) | $(5.135) billion | $1.112 billion |
| Net income (loss) attributable to AmerisourceBergen | $(3.409) billion | $855.4 million |
| Diluted EPS | $(16.65) | $4.04 |
| Cash from operations | $2.207 billion | $2.344 billion |
| Capital expenditures | $369.7 million | $310.2 million |
| Cash and cash equivalents at year-end | $4.598 billion | $3.374 billion |
| Total debt at year-end | $4.120 billion | $4.173 billion |
Revenue rose 5.7%; gross profit rose 1.0%. Consolidated gross margin was approximately 2.73%, versus 2.86% in FY2019. Reported operating and net losses primarily reflect the opioid-litigation accrual, not a collapse in underlying segment results: segment operating income increased 7.5% to $2.204 billion. Pharmaceutical Distribution Services segment operating income increased 8.1% to $1.807 billion; Other increased 5.1% to $400.1 million.
For the fourth quarter, revenue was $49.245 billion, operating loss was $6.113 billion, net loss was $4.845 billion, and diluted loss per share was $23.74. The quarter included the $6.6 billion opioid-related charge.
Material changes versus the prior period
- Revenue growth was driven principally by pharmaceutical distribution, including higher specialty-product sales and increased sales to Walgreens and specialty physician practices. Other-segment revenue grew 9.6%.
- Operating expenses increased sharply, mainly because employee severance, litigation, and other costs included a $6.6 billion opioid-litigation accrual. PharMEDium asset impairments were $361.7 million, compared with $570.0 million in FY2019.
- Operating cash flow declined to $2.207 billion. It included a substantial non-cash increase in the accrued litigation liability and significant working-capital movements, including higher receivables and inventory.
- Year-end stockholders’ equity became a deficit of $839.6 million, versus positive equity of $2.993 billion in FY2019, largely reflecting the litigation charge and share repurchases.
Outlook, risks, contingencies, and unusual items
- Management expected FY2021 revenue growth in the mid-single digits and capital expenditures of approximately $400 million. The filing provides no clear FY2021 earnings guidance.
- The company recorded a $6.6 billion opioid-litigation charge, including a proposed company payment of approximately $6.5 billion over 18 years if the contemplated global settlement is completed. The settlement remained subject to contingencies; the company said the ultimate loss could differ materially and it could not estimate possible losses beyond the amount accrued. Approximately $408 million was estimated payable before September 30, 2021, with $6.2 billion recorded as a long-term litigation liability.
- COVID-19 had adversely affected, and could continue to affect, demand, supply, distribution operations, customer credit and collections, and business projects. Management could not predict the pandemic’s duration or full financial impact.
- The company permanently exited PharMEDium’s compounding business in FY2020 following ongoing operational, regulatory, and commercial challenges.
- Customer concentration is material: Walgreens accounted for approximately 33% of annual revenue and 47% of net accounts receivable; Express Scripts accounted for approximately 12% of revenue. The Walgreens distribution and generic-purchasing arrangements run through 2026.
- Liquidity included $4.598 billion of cash and approximately $2.614 billion of additional availability under specified credit facilities at year-end. The company reported compliance with debt covenants and stated that the opioid accrual was not expected to affect covenant compliance or dividend capacity. It repaid a $400 million term loan in October 2020.
- Other exposures include pharmaceutical pricing and reimbursement changes, opioid investigations and lawsuits, customer and supplier credit risk, regulatory compliance, and information-security risks.
Important facts for investors to verify
- Whether the contemplated opioid settlement is finalized, which parties participate, the ultimate payment schedule and terms, and any additional exposure beyond the recorded accrual.
- Whether FY2021 revenue achieves management’s mid-single-digit growth outlook, and how COVID-19 and pharmaceutical pricing affect segment profitability and cash conversion.
- Walgreens relationship economics, contract terms, and the concentration of receivables and revenue in major customers.
- Cash-flow sustainability after adjusting for litigation-liability accruals and working-capital changes, alongside debt maturities, facility availability, and planned capital returns.
- Whether PharMEDium exit costs, impairment-related effects, and remaining regulatory obligations are fully reflected in reported results.